Market Closed -
OTC Markets
02:31:14 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
0.0043
USD
|
+65.38%
|
|
-42.67%
|
-80.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
64.71
|
26.5
|
18.54
|
1.765
|
Enterprise Value (EV)
1 |
47.74
|
5.936
|
12.19
|
4.441
|
P/E ratio
|
-
|
-0.26
x
|
-0.76
x
|
-0.02
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
53,752,130
x
|
17,166,258
x
|
1,390,481
x
|
EV / Revenue
|
-
|
53,752,088
x
|
17,166,252
x
|
1,390,484
x
|
EV / EBITDA
|
-1.64
x
|
-0.49
x
|
-0.36
x
|
-0.05
x
|
EV / FCF
|
-1,811,097
x
|
-1,499,514
x
|
-572,591
x
|
-175,341
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-3.87
x
|
-3.32
x
|
1.63
x
|
-0.21
x
|
Nbr of stocks (in thousands)
|
6.68
|
18.7
|
60.4
|
555
|
Reference price
2 |
9,688
|
1,414
|
306.9
|
3.180
|
Announcement Date
|
2/13/20
|
2/16/21
|
3/16/22
|
2/23/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
0.493
|
1.08
|
1.269
|
EBITDA
1 |
-48.19
|
-64.64
|
-39.39
|
-53.7
|
-52.14
|
-35.58
|
EBIT
1 |
-48.26
|
-65.04
|
-39.87
|
-54.11
|
-52.38
|
-35.74
|
Operating Margin
|
-
|
-
|
-
|
-10,975.05%
|
-4,849.63%
|
-2,816.63%
|
Earnings before Tax (EBT)
1 |
-61.08
|
-73.67
|
-32.56
|
-76.1
|
-19.77
|
-58.8
|
Net income
1 |
-61.08
|
-73.67
|
-32.56
|
-76.1
|
-19.77
|
-58.8
|
Net margin
|
-
|
-
|
-
|
-15,436.11%
|
-1,830.46%
|
-4,633.18%
|
EPS
|
-
|
-
|
-
|
-5,504
|
-405.4
|
-177.3
|
Free Cash Flow
|
-
|
-61.15
|
-35.73
|
-17.67
|
-32.38
|
-10.06
|
FCF margin
|
-
|
-
|
-
|
-3,584.63%
|
-2,998%
|
-793.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/5/19
|
11/5/19
|
2/13/20
|
2/16/21
|
3/16/22
|
2/23/23
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
0.201
|
0.281
|
0.4
|
0.422
|
0.3
|
0.238
|
0.31
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.32
|
-16.38
|
30.01
|
-
|
-6.972
|
-
|
-8.6
|
-4.688
|
-7.045
|
-1.776
|
Operating Margin
|
-8,117.41%
|
-5,829.18%
|
7,503%
|
-
|
-2,324%
|
-
|
-2,774.19%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-15.33
|
-16.96
|
27.01
|
-
|
-7.531
|
-
|
-9.249
|
11.4
|
-7.301
|
-
|
Net income
1 |
-15.33
|
-16.96
|
27.01
|
-
|
-7.531
|
-
|
-9.249
|
11.4
|
-7.375
|
-1.934
|
Net margin
|
-7,626.37%
|
-6,036.3%
|
6,753%
|
-
|
-2,510.33%
|
-
|
-2,983.55%
|
-
|
-
|
-
|
EPS
2 |
-280.0
|
-280.0
|
532.4
|
-126.8
|
-42.00
|
-98.80
|
-12.33
|
4.910
|
-1.510
|
-0.3000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/5/21
|
11/4/21
|
3/16/22
|
5/5/22
|
8/11/22
|
11/8/22
|
2/23/23
|
5/11/23
|
8/16/23
|
11/20/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
2.68
|
Net Cash position
|
-
|
-
|
17
|
20.6
|
6.35
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.0752
x
|
Free Cash Flow
|
-
|
-61.1
|
-35.7
|
-17.7
|
-32.4
|
-10.1
|
ROE (net income / shareholders' equity)
|
-
|
113%
|
76.5%
|
483%
|
2,514%
|
1,067%
|
ROA (Net income/ Total Assets)
|
-
|
-120%
|
-55.9%
|
-55%
|
-53.7%
|
-70.6%
|
Assets
1 |
-
|
61.42
|
58.29
|
138.3
|
36.84
|
83.31
|
Book Value Per Share
|
-
|
-
|
-2,504
|
-426.0
|
188.0
|
-14.90
|
Cash Flow per Share
|
-
|
-
|
2,656
|
872.0
|
226.0
|
3.240
|
Capex
1 |
0.77
|
3.37
|
1.32
|
0.64
|
0.2
|
0.02
|
Capex / Sales
|
-
|
-
|
-
|
129.61%
|
18.8%
|
1.58%
|
Announcement Date
|
11/5/19
|
11/5/19
|
2/13/20
|
2/16/21
|
3/16/22
|
2/23/23
|
|
1st Jan change
|
Capi.
|
---|
| -80.45% | 226K | | +17.09% | 44.63B | | +43.00% | 40.46B | | -9.70% | 38.07B | | +33.28% | 32.27B | | -8.98% | 27.3B | | +13.37% | 26.53B | | +44.11% | 14.06B | | +32.33% | 12.54B | | -7.26% | 11.28B |
Other Biotechnology & Medical Research
|